These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 25124541)

  • 1. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis.
    Yang XP; Lai D; Zhong XY; Shen HP; Huang YL
    Eur J Clin Pharmacol; 2014 Oct; 70(10):1149-58. PubMed ID: 25124541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
    Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
    Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
    Nisly SA; Kolanczyk DM; Walton AM
    Am J Health Syst Pharm; 2013 Feb; 70(4):311-9. PubMed ID: 23370138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
    Bode B; Stenlöf K; Harris S; Sullivan D; Fung A; Usiskin K; Meininger G
    Diabetes Obes Metab; 2015 Mar; 17(3):294-303. PubMed ID: 25495720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
    Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G
    Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
    Forst T; Guthrie R; Goldenberg R; Yee J; Vijapurkar U; Meininger G; Stein P
    Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Yue D; David-Neto E; Xi L; Figueroa K; Wajs E; Usiskin K; Meininger G
    Diabetes Obes Metab; 2013 May; 15(5):463-73. PubMed ID: 23464594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Lajara R
    Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.
    Inagaki N; Kondo K; Yoshinari T; Takahashi N; Susuta Y; Kuki H
    Expert Opin Pharmacother; 2014 Aug; 15(11):1501-15. PubMed ID: 25010793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Stenlöf K; Cefalu WT; Kim KA; Alba M; Usiskin K; Tong C; Canovatchel W; Meininger G
    Diabetes Obes Metab; 2013 Apr; 15(4):372-82. PubMed ID: 23279307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes.
    Elmore LK; Baggett S; Kyle JA; Skelley JW
    Consult Pharm; 2014; 29(5):335-46. PubMed ID: 24849690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S
    Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
    Schernthaner G; Gross JL; Rosenstock J; Guarisco M; Fu M; Yee J; Kawaguchi M; Canovatchel W; Meininger G
    Diabetes Care; 2013 Sep; 36(9):2508-15. PubMed ID: 23564919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.
    Musso G; Gambino R; Cassader M; Pagano G
    Ann Med; 2012 Jun; 44(4):375-93. PubMed ID: 21495788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
    Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
    Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.